Earlier this year, members of the Cambridge Cognition team were co-authors on a paper describing a protocol for the Better Understanding the Metamorphosis of Pregnancy (BUMP) study. This study, led by 4YouandMe, is aiming to use digital tools, some of which are provided by Cambridge Cognition, to gain a deeper understanding of the symptoms of pregnancy. Here, we explain the study's aims and why it is important. You can find the full paper here.
At AAIC 2019 we presented an interim analysis of online screening as a recruitment strategy for the MOPEAD initiative. The initial findings are positive, with high levels of engagement from older adults, as well as sensitivity to impairment.
With more than two million participants, Dementias Platform UK is a national effort to make real strides in tackling dementia. Leona Wolters from the initiative shared with us the vital role that CANTAB plays in this large-scale cohort study.
To date, no effective drugs have been developed to address cognitive dysfunction in schizophrenia. Here we will highlight the three main methodological challenges which may be contributing to these high failure rates, and propose potential practical solutions to these problems.
Screening patients into early stage Alzheimer’s trials can be costly and time-consuming. Kenton Zavitz, PhD, Director of Clinical Affairs proposes a potential solution for improving recruitment into clinical trials.
We’re pleased to announce that our CANTAB Recruit software is now established in two major Phase III trials into Alzheimer’s disease.
Cambridge Cognition are attending the Schizophrenia International Research Society Conference (SIRS): 4th - 8th April 2018
Dr Kenton Zavitz, Director of Clinical Affairs at Cambridge Cognition, and Dr Robert Smith, Consultant Neuropsychologist, hosted a webinar to discuss clinical trials for early Alzheimer’s disease.
Join them to hear more about overcoming the barriers to expedite the drug development process.
Tuesday 22nd May 2018, 11 a.m. EDT
New data demonstrates possibility for speech recognition and online assessments to enhance clinical trials in Alzheimer’s disease.
Identifying participants in the ‘pre-clinical’ or ‘prodromal’ stage of Alzheimer's disease prior to the onset of cognitive and functional decline can be challenging, time-consuming and expensive. Can, pre-screening for episodic memory deficits enrich the recruitment of eligible participants in early Alzheimer’s disease clinical trials?
Dr Rosemary Abbott presented this poster at the International Conference on Alzheimer's & Parkinson's Disease on the 31st March 2017.